Vemurafenib (Zelboraf), dabrafenib (Tafinlar), and encorafenib (Braftovi) are drugs that target the BRAF protein directly. These drugs can often be helpful for people whose melanoma has spread or can’t be …

Feb 24, 2023 · Targeted drugs called BRAF and MEK inhibitors can be used to treat melanoma. Learn about them, the side effects and how to prepare for treatment.

Jul 24, 2025 · Common BRAF inhibitors include vemurafenib, dabrafenib, and encorafenib. These drugs bind to the active form of the mutated BRAF kinase, anchoring themselves in its ATP-binding site …

BRAF inhibitors are drugs that can shrink or slow the growth of metastatic melanoma in people whose tumors have a BRAF mutation. BRAF inhibitors include v emurafenib (Zelboraf®), dabrafenib …

BRAF-V600E BRAF V600E is a determinant of sensitivity to proteasome inhibitors. Vulnerability to proteasome inhibitors is dependent on persistent BRAF signaling, because BRAF-V600E blockade …

These efforts have led to the development and regulatory approval of three BRAF inhibitors as well as five combinations of a BRAF inhibitor plus an additional agent (s) to manage cancer such as …

Apr 16, 2024 · In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, …

In depth description about different heterocyclic scaffolds (quinoline, imidazole, pyridine, triazole, pyrrole etc.) as BRAF inhibitors from the last five years (2018–2023) highlighting the structure-activity …

Blocking mutated BRAF kinase proteins may help keep cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. A substance that blocks a protein called BRAF. BRAF is a kinase …

BRAF inhibitors are a class of targeted therapy drugs designed to inhibit the activity of the BRAF protein, a key player in the MAPK/ERK signaling pathway. Mutations in the BRAF gene, particularly the …